Blue-yellow colour vision in an onchocercal area of northern Nigeria

Onchocerciasis as a risk factor for night blindness

PURPOSE

In the Kaduna State Nigeria Onchocerciasis focus, the prevalence of reported night blindness (RNB) was 12.9%, higher than the national average (1%), and a control non-onchocercal community (0.83%, P < 0.0001). Risk factors for RNB were explored.

METHODS

This was an analysis of baseline data from the phase three ivermectin trials in Kaduna (1988-1995). 6831 subjects in the onchocercal zone and 1563 in the control zone were examined. Ordinal logistic regression was used to assess the relationship between microfilaria load (uninfected, low (<10 mf/mg), moderate (10-49 mf/mg) and high (50+ mf/mg)) and likelihood of RNB.

RESULTS

Ocular evidence of vitamin A deficiency (Bitot spots or xerophthalmia) was absent in both populations. The excess risk of nightblindness attributable to domicile in this onchocerciasis-endemic area was 11.9% with a population attributable fraction of 92.2%. The prevalence of RNB and age-adjusted odds ratio increased with higher microfilaria load (P < 0.0027.) Subjects with onchocerciasis-related ocular lesions such as optic nerve disease (OND; age-adjusted OR 2.29, 95% confidence interval, CI, 1.86-2.83), sclerosing keratitis (OR 2.75, 95% CI 2.10-3.50), and onchocercal chorioretinitis (OR 1.66, 95% CI 1.22-2.26) were significantly more likely to report night blindness. Overall, subjects with a primary diagnosis of 'ocular onchocerciasis' were 50% more likely to report night blindness. OND, cataract and trachoma together accounted for 52% of all RNB but OND (onchocerciasis-related in 80% of cases) emerged as the single most common associated pathology in 30% of cases.

CONCLUSIONS

Onchocercal infection probably accounted for the excess of RNB in this focus.

The Problem of Trachoma within an Onchocerciasis-Endemic Zone in Kaduna: Need for a Multilateral Approach?

INTRODUCTION

Within the mesoendemic onchocerciasis belt of Kaduna State, Northern Nigeria, there were other causes of ocular morbidity as well. We investigated the contribution of trachoma.

METHODS

A total of 6831 individuals were examined for eye disease, including signs of trachoma.

RESULTS

The overall prevalence of trachoma was 4.5% (577 eyes of 310 individuals), making it the second most common cause (1 in 5) of ocular morbidity after cataracts. Of the 577 eyes, 405 (70.2%) had cicatrizing disease while the rest had active disease. Overall, the prevalence of TF was 1.1% (1.3% in those < 10 years of age), TI 0.2%, TS 3%, CO 0.5% and TT 1.1% (4.3% and 3.5% in subjects aged > 55 and > 40 years, respectively). The prevalence of trachoma increased with age. The overall prevalence of blindness in the whole population was 2.7%. Trachoma accounted for 11% of this. On the other hand, onchocerciasis accounted for 3.1% of the overall ocular morbidity (less than trachoma) and 39% of the blindness.

CONCLUSIONS

There appears to be a clear need to retrain middle cadre ivermectin workers in trachoma rapid assessment and SAFE strategy intervention methods in order to further impact blindness prevention in these 'onchocerciasis-endemic' zones.

A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results

A three-year randomized, controlled, double-blind trial was conducted in Cameroon to determine whether ivermectin, given at three-monthly intervals and/or at high doses (800 microg/kg), had a greater effect on adult Onchocerca volvulus than standard doses (150 microg/kg annually). As several patients complained of transitory subjective visual problems after treatment, some of them being of an unexpected type, we organized two series of detailed ophthalmological examinations to evaluate whether they were associated with ocular lesions. Analysis showed that these complaints were significantly more frequent in the two groups treated with high doses of ivermectin than in the reference group. In the ophthalmological examinations, the only differences recorded between the groups were a lower prevalence and mean number of microfilariae in the anterior chamber in the groups treated three-monthly, and, at the first examination round, a higher prevalence of early lesions of the iris in the group treated at high doses annually. These findings do not allow us to explain the cause of the transitory ocular complaints, nor why they were more frequent in the groups treated at high doses. However, one may conclude that using doses of ivermectin higher than the standard one should be considered with caution.